Electrical ablation enhances CAR‑NK cell therapy for liver cancer

IRE creates a gateway for immune cells

A team from Sungkyunkwan University in South Korea has shown that combining irreversible electroporation (IRE) with lipid‑nanoparticle‑delivered CAR‑NK cells targeting glypican‑3 (GPC3) can effectively treat hepatocellular carcinoma (HCC) in mouse models. The study, published this month, demonstrates a new way to attack solid tumors that resist conventional treatments.

The researchers first applied IRE, a non‑thermal electrical ablation technique that creates microscopic pores in tumor cells, to liver tumors in mice. They then administered anti‑GPC3 CAR‑NK cells encapsulated in lipid nanoparticles (LNPs). The combination produced a significantly higher tumor‑free survival rate compared with either therapy alone. The team attributes the improved outcome to IRE’s ability to disrupt the tumor microenvironment and enhance immune cell infiltration.

Irreversible electroporation works by delivering short, high‑intensity electric pulses that permanently permeabilize cell membranes. Unlike heat‑based ablation, IRE preserves the extracellular matrix and vascular structures, allowing immune cells to penetrate deeper into the tumor. In this study, the authors observed a marked increase in NK cell infiltration after IRE, suggesting that the technique creates a more permissive niche for the engineered cells.

CAR‑NK cells target GPC3, a liver‑cancer marker

„IRE changes the tumor landscape,” said lead investigator Dr. Kim. „It removes physical barriers and releases danger signals that attract immune cells, making the tumor more vulnerable to CAR‑NK attack.”

Glypican‑3 is overexpressed on most HCC cells but is rare in normal tissues, making it an ideal target for cell‑based immunotherapy. The team engineered natural killer (NK) cells to express a chimeric antigen receptor (CAR) that recognizes GPC3. To improve delivery, they packaged the CAR‑NK cells in lipid nanoparticles, which protect the cells during circulation and facilitate their homing to the tumor site.

How does the combination work?

In mouse experiments, the LNP‑CAR‑NK cells alone reduced tumor growth, but when combined with IRE, the reduction was dramatic. Tumor‑free survival at 60 days reached 80% in the combination group, compared with 30% for IRE alone and 20% for CAR‑NK cells alone.

The study proposes a two‑step mechanism. First, IRE disrupts the tumor’s physical and immunosuppressive barriers. Second, the CAR‑NK cells recognize and kill GPC3‑expressing cells. The lipid nanoparticles help the NK cells survive the harsh tumor environment and deliver them efficiently to the ablation site. The researchers also noted that the combination induced a systemic immune response, suggesting potential for treating metastatic disease.

„By using IRE to open the door and CAR‑NK cells to deliver the blow, we can overcome the resistance that many solid tumors exhibit,” explained Dr. Kim.

Is this a breakthrough for hard‑to‑treat cancers?

The findings point to a promising strategy for patients whose tumors do not respond to surgery, radiation, or checkpoint inhibitors. While the work is still preclinical, the authors believe the approach could translate to human trials soon. They plan to test the therapy in larger animal models and evaluate safety profiles before moving to phase I studies.

The combination also offers a modular platform. Other tumor antigens can be targeted by designing different CARs, and the LNP delivery system can be adapted for various cell types. This flexibility could accelerate the development of personalized immunotherapies for a range of solid tumors.

Frequently Asked Questions

What is the main advantage of combining IRE with CAR‑NK cells? IRE preserves the tumor’s structural integrity while creating pores that allow immune cells to infiltrate. This enhances the effectiveness of CAR‑NK cells that target tumor‑specific antigens.

Why use lipid nanoparticles to deliver CAR‑NK cells? LNPs protect the engineered NK cells during circulation, improve their homing to the tumor site, and reduce off‑target effects, making the therapy safer and more efficient.

Will this approach work for all liver cancers? The current study focused on GPC3‑positive HCC in mice. Human trials are needed to confirm efficacy across different patient populations and tumor subtypes.